Abstract Background Sclerostin (Scl) has recently emerged as a novel marker of bone
remodeling and vascular calcification. However, whether high circulating Scl is also a risk
factor for death is not well established. The purpose of this study was to test whether serum
Scl would be associated with mortality. Methods we measured serum Scl in a hemodialysis
patients' cohort, which was followed during a ten-year period. Competing risk regression
models were applied, as during the follow-up, patients were exposed to both events kidney …

Background Sclerostin (Scl) has recently emerged as a novel marker of bone remodeling
and vascular calcification. However, whether high circulating Scl is also a risk factor for
death is not well established. The purpose of this study was to test whether serum Scl would
be associated with mortality. Methods we measured serum Scl in a hemodialysis patients'
cohort, which was followed during a ten-year period. Competing risk regression models
were applied, as during the follow-up, patients were exposed to both events kidney …